Breast cancer (BC) is the most commonly diagnosed cancer in women worldwide. 1 It is a
heterogeneous disease, comprising distinct biologic entities with different prognosis and …

The peptide‐based therapeutic cancer vaccines have attracted enormous attention in recent
years as one of the effective treatments of tumour immunotherapy. Most of peptide‐based …

Cytokine-based immunotherapy is a promising field in the cancer treatment, since cytokines,
as proteins of the immune system, are able to modulate the host immune response toward …

Objectives Recent clinical trials have demonstrated significant clinical benefits from novel
therapeutic compounds in breast cancer patient with human epidermal growth factor …

Novel anti-HER2 antibody-drug conjugates trastuzumab deruxtecan (DS-8201a) showed its
effect in previously-treated HER2-low metastatic breast cancer, suggesting a promising …

Clinical progress in the field of HER2-positive breast cancer therapy has been dramatically
improved by understanding of the immune regulatory mechanisms of tumor …

Breast cancer is the leading cause of death in women from 20 to 59 years old. The
conventional treatment includes surgery, chemotherapy, hormonal therapy, and …

Abstract Background The E75 and GP2 vaccines are the few therapeutic vaccines targeting
HER2 currently under clinical research for patients with breast cancer. Methods Databases …

HER2-targeted therapy has not benefited patients with low levels of HER2 expression;
however, combination therapy may be effective. Primary analysis of a phase IIb trial …

Many immune suppressive mechanisms utilized by triple negative breast cancer (TNBC) are
regulated by oncogenic epithelial-to-mesenchymal transition (EMT). How TNBC EMT …